<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03320000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P00519</UniProt_ID>
  <Seq_Length>1130</Seq_Length>
  <Molecule_Weight>122873</Molecule_Weight>
  <KEGG_ID>hsa:25</KEGG_ID>
  <Orthology_ID>K06619</Orthology_ID>
  <EBI_ID>EBI-375543</EBI_ID>
  <Function_Summary>Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF08919:F_actin_bind@@PF07714:Pkinase_Tyr@@PF00017:SH2@@PF00018:SH3_1</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>147</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>C-Abl</Alias>
      <Alias>C-Abl tyrosine kinase</Alias>
      <Alias>C-Abl kinase</Alias>
      <Alias>P150</Alias>
      <Alias>Proto-oncogene c-Abl</Alias>
      <Alias>Proto-oncogene tyrosine-protein kinase ABL1</Alias>
      <Alias>Abelson murine leukemia viral oncogene homolog 1</Alias>
      <Alias>Bcr/c-abl oncogene protein</Alias>
      <Alias>V-abl Abelson murine leukemia viral oncogene homolog 1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein C-terminus, the end of any peptide chain at which the 1-carboxy function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue.</Detail>
      <Keyword>Protein C-terminus binding</Keyword>
      <Ontology_ID>GO:0008022</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a non-membrane spanning protein L-tyrosine = ADP + a non-membrane spanning protein L-tyrosine phosphate.</Detail>
      <Keyword>Non-membrane spanning protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004715</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a proline-rich region, i.e. a region that contains a high proportion of proline residues, in a protein.</Detail>
      <Keyword>Proline-rich region binding</Keyword>
      <Ontology_ID>GO:0070064</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with magnesium (Mg) ions.</Detail>
      <Keyword>Magnesium ion binding</Keyword>
      <Ontology_ID>GO:0000287</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a mitogen-activated protein kinase.</Detail>
      <Keyword>Mitogen-activated protein kinase binding</Keyword>
      <Ontology_ID>GO:0051019</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with manganese (Mn) ions.</Detail>
      <Keyword>Manganese ion binding</Keyword>
      <Ontology_ID>GO:0030145</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a SH3 domain (Src homology 3) of a protein, small protein modules containing approximately 50 amino acid residues found in a great variety of intracellular or membrane-associated proteins.</Detail>
      <Keyword>SH3 domain binding</Keyword>
      <Ontology_ID>GO:0017124</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + nicotinate ribonucleotide = diphosphate + deamido-NAD+.</Detail>
      <Keyword>Nicotinate-nucleotide adenylyltransferase activity</Keyword>
      <Ontology_ID>GO:0004515</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with monomeric actin, also known as G-actin.</Detail>
      <Keyword>Actin monomer binding</Keyword>
      <Ontology_ID>GO:0003785</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>47</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>900</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>810</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>852</Position>
      <Original>Thr</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>972</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>706</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>247</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>140</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>968</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>166</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.</Detail>
      <Keyword>DNA repair</Keyword>
      <Ontology_ID>GO:0006281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A system for the correction of errors in which an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. The mismatch repair system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops and heterologies generated during DNA replication and recombination.</Detail>
      <Keyword>Mismatch repair</Keyword>
      <Ontology_ID>GO:0006298</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.</Detail>
      <Keyword>Response to DNA damage stimulus</Keyword>
      <Ontology_ID>GO:0006974</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of a muscle cell.</Detail>
      <Keyword>Muscle cell differentiation</Keyword>
      <Ontology_ID>GO:0042692</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.</Detail>
      <Keyword>Peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0018108</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The widespread phosphorylation of various molecules, triggering many downstream processes, that occurs in response to the detection of DNA damage.</Detail>
      <Keyword>DNA damage induced protein phosphorylation</Keyword>
      <Ontology_ID>GO:0006975</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of actin cytoskeleton reorganization.</Detail>
      <Keyword>Regulation of actin cytoskeleton reorganization</Keyword>
      <Ontology_ID>GO:2000249</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of attachment of a cell to another cell or to the extracellular matrix.</Detail>
      <Keyword>Regulation of cell adhesion</Keyword>
      <Ontology_ID>GO:0030155</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of muscle cell differentiation.</Detail>
      <Keyword>Positive regulation of muscle cell differentiation</Keyword>
      <Ontology_ID>GO:0051149</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cell motility.</Detail>
      <Keyword>Regulation of cell motility</Keyword>
      <Ontology_ID>GO:2000145</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered.</Detail>
      <Keyword>Positive regulation of oxidoreductase activity</Keyword>
      <Ontology_ID>GO:0051353</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.</Detail>
      <Keyword>Actin cytoskeleton organization</Keyword>
      <Ontology_ID>GO:0030036</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of endocytosis.</Detail>
      <Keyword>Regulation of endocytosis</Keyword>
      <Ontology_ID>GO:0030100</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.</Detail>
      <Keyword>Autophagy</Keyword>
      <Ontology_ID>GO:0006914</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.</Detail>
      <Keyword>Cell adhesion</Keyword>
      <Ontology_ID>GO:0007155</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.</Detail>
      <Keyword>Regulation of autophagy</Keyword>
      <Ontology_ID>GO:0010506</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of processes initiated by the detection of DNA damage and resulting in the induction of apoptosis (programmed cell death).</Detail>
      <Keyword>DNA damage response, signal transduction resulting in induction of apoptosis</Keyword>
      <Ontology_ID>GO:0008630</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of protein serine/threonine kinase activity.</Detail>
      <Keyword>Negative regulation of protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0071901</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cell cycle process that regulates transcription such that the target genes are transcribed as part of the S phase of the mitotic cell cycle.</Detail>
      <Keyword>Regulation of transcription involved in S phase of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0000115</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.</Detail>
      <Keyword>Endocytosis</Keyword>
      <Ontology_ID>GO:0006897</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>855</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>253</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>852</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>618</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>613</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>683</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>185</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>735</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>569</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>949</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>226</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>936</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>394</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>781</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>393</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>659</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>50</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>620</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>392</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>264</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>257</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>469</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>919</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>711</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>805</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>844</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>70</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>718</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>977</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>814</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>446</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>619</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>809</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>917</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR</Protein_Seq>
    <DNA_Seq>GGCCTTCCCCCTGCGAGGATCGCCGTTGGCCCGGGTTGGCTTTGGAAAGCGGCGGTGGCTTTGGGCCGGGCTCGGCCTCGGGAACGCCAGGGGCCCCTGGGTGCGGACGGGCGCGGCCAGGAGGGGGTTAAGGCGCAGGCGGCGGCGGGGCGGGGGCGGGCCTGGCGGGCGCCCTCTCCGGGCCCTTTGTTAACAGGCGCGTCCCGGCCAGCGGAGACGCGGCCGCCCTGGGCGGGCGCGGGCGGCGGGCGGCGGTGAGGGCGGCCTGCGGGGCGGCGCCCGGGGGCCGGGCCGAGCCGGGCCTGAGCCGGGCCCGGACCGAGCTGGGAGAGGGGCTCCGGCCCGATCGTTCGCTTGGCGCAAAATGTTGGAGATCTGCCTGAAGCTGGTGGGCTGCAAATCCAAGAAGGGGCTGTCCTCGTCCTCCAGCTGTTATCTGGAAGAAGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAGCCGCTCGTTGGAACTCCAAGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTTTCGTTGCACTGTATGATTTTGTGGCCAGTGGAGATAACACTCTAAGCATAACTAAAGGTGAAAAGCTCCGGGTCTTAGGCTATAATCACAATGGGGAATGGTGTGAAGCCCAAACCAAAAATGGCCAAGGCTGGGTCCCAAGCAACTACATCACGCCAGTCAACAGTCTGGAGAAACACTCCTGGTACCATGGGCCTGTGTCCCGCAATGCCGCTGAGTATCCGCTGAGCAGCGGGATCAATGGCAGCTTCTTGGTGCGTGAGAGTGAGAGCAGTCCTAGCCAGAGGTCCATCTCGCTGAGATACGAAGGGAGGGTGTACCATTACAGGATCAACACTGCTTCTGATGGCAAGCTCTACGTCTCCTCCGAGAGCCGCTTCAACACCCTGGCCGAGTTGGTTCATCATCATTCAACGGTGGCCGACGGGCTCATCACCACGCTCCATTATCCAGCCCCAAAGCGCAACAAGCCCACTGTCTATGGTGTGTCCCCCAACTACGACAAGTGGGAGATGGAACGCACGGACATCACCATGAAGCACAAGCTGGGCGGGGGCCAGTACGGGGAGGTGTACGAGGGCGTGTGGAAGAAATACAGCCTGACGGTGGCCGTGAAGACCTTGAAGGAGGACACCATGGAGGTGGAAGAGTTCTTGAAAGAAGCTGCAGTCATGAAAGAGATCAAACACCCTAACCTAGTGCAGCTCCTTGGGGTCTGCACCCGGGAGCCCCCGTTCTATATCATCACTGAGTTCATGACCTACGGGAACCTCCTGGACTACCTGAGGGAGTGCAACCGGCAGGAGGTGAACGCCGTGGTGCTGCTGTACATGGCCACTCAGATCTCGTCAGCCATGGAGTACCTAGAGAAGAAAAACTTCATCCACAGAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAGCTGATTTTGGCCTGAGCAGGTTGATGACAGGGGACACCTACACAGCCCATGCTGGAGCCAAGTTCCCCATCAAATGGACTGCACCCGAGAGCCTGGCCTACAACAAGTTCTCCATCAAGTCCGACGTCTGGGCATTTGGAGTATTGCTTTGGGAAATTGCTACCTATGGCATGTCCCCTTACCCGGGAATTGACCGTTCCCAGGTGTATGAGCTGCTAGAGAAGGACTACCGCATGAAGCGCCCAGAAGGCTGCCCAGAGAAGGTCTATGAACTCATGCGAGCATGTTGGCAGTGGAATCCCTCTGACCGGCCCTCCTTTGCTGAAATCCACCAAGCCTTTGAAACAATGTTCCAGGAATCCAGTATCTCAGACGAAGTGGAAAAGGAGCTGGGGAAACAAGGCGTCCGTGGGGCTGTGACTACCTTGCTGCAGGCCCCAGAGCTGCCCACCAAGACGAGGACCTCCAGGAGAGCTGCAGAGCACAGAGACACCACTGACGTGCCTGAGATGCCTCACTCCAAGGGCCAGGGAGAGAGCGATCCTCTGGACCATGAGCCTGCCGTGTCTCCATTGCTCCCTCGAAAAGAGCGAGGTCCCCCGGAGGGCGGCCTGAATGAAGATGAGCGCCTTCTCCCCAAAGACAAAAAGACCAACTTGTTCAGCGCCTTGATCAAGAAGAAGAAGAAGACAGCCCCAACCCCTCCCAAACGCAGCAGCTCCTTCCGGGAGATGGACGGCCAGCCGGAGCGCAGAGGGGCCGGCGAGGAAGAGGGCCGAGACATCAGCAACGGGGCACTGGCTTTCACCCCCTTGGACACAGCTGACCCAGCCAAGTCCCCAAAGCCCAGCAATGGGGCTGGGGTCCCCAATGGAGCCCTCCGGGAGTCCGGGGGCTCAGGCTTCCGGTCTCCCCACCTGTGGAAGAAGTCCAGCACGCTGACCAGCAGCCGCCTAGCCACCGGCGAGGAGGAGGGCGGTGGCAGCTCCAGCAAGCGCTTCCTGCGCTCTTGCTCCGTCTCCTGCGTTCCCCATGGGGCCAAGGACACGGAGTGGAGGTCAGTCACGCTGCCTCGGGACTTGCAGTCCACGGGAAGACAGTTTGACTCGTCCACATTTGGAGGGCACAAAAGTGAGAAGCCGGCTCTGCCTCGGAAGAGGGCAGGGGAGAACAGGTCTGACCAGGTGACCCGAGGCACAGTAACGCCTCCCCCCAGGCTGGTGAAAAAGAATGAGGAAGCTGCTGATGAGGTCTTCAAAGACATCATGGAGTCCAGCCCGGGCTCCAGCCCGCCCAACCTGACTCCAAAACCCCTCCGGCGGCAGGTCACCGTGGCCCCTGCCTCGGGCCTCCCCCACAAGGAAGAAGCCTGGAAAGGCAGTGCCTTAGGGACCCCTGCTGCAGCTGAGCCAGTGACCCCCACCAGCAAAGCAGGCTCAGGTGCACCAAGGGGCACCAGCAAGGGCCCCGCCGAGGAGTCCAGAGTGAGGAGGCACAAGCACTCCTCTGAGTCGCCAGGGAGGGACAAGGGGAAATTGTCCAAGCTCAAACCTGCCCCGCCGCCCCCACCAGCAGCCTCTGCAGGGAAGGCTGGAGGAAAGCCCTCGCAGAGGCCCGGCCAGGAGGCTGCCGGGGAGGCAGTCTTGGGCGCAAAGACAAAAGCCACGAGTCTGGTTGATGCTGTGAACAGTGACGCTGCCAAGCCCAGCCAGCCGGCAGAGGGCCTCAAAAAGCCCGTGCTCCCGGCCACTCCAAAGCCACACCCCGCCAAGCCGTCGGGGACCCCCATCAGCCCAGCCCCCGTTCCCCTTTCCACGTTGCCATCAGCATCCTCGGCCTTGGCAGGGGACCAGCCGTCTTCCACTGCCTTCATCCCTCTCATATCAACCCGAGTGTCTCTTCGGAAAACCCGCCAGCCTCCAGAGCGGGCCAGCGGCGCCATCACCAAGGGCGTGGTCTTGGACAGCACCGAGGCGCTGTGCCTCGCCATCTCTGGGAACTCCGAGCAGATGGCCAGCCACAGCGCAGTGCTGGAGGCCGGCAAAAACCTCTACACGTTCTGCGTGAGCTATGTGGATTCCATCCAGCAAATGAGGAACAAGTTTGCCTTCCGAGAGGCCATCAACAAACTGGAGAATAATCTCCGGGAGCTTCAGATCTGCCCGGCGTCAGCAGGCAGTGGTCCGGCGGCCACTCAGGACTTCAGCAAGCTCCTCAGTTCGGTGAAGGAAATCAGTGACATAGTGCAGAGGTAGCAGCAGTCAGGGGTCAGGTGTCAGGCCCGTCGGAGCTGCCTGCAGCACATGCGGGCTCGCCCATACCCATGACAGTGGCTGAG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoskeleton</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ABL1</Gene_Name>
    <Gene_Alias>ABL; JTK7</Gene_Alias>
    <Gene_ID>25</Gene_ID>
    <Genbank_ACCN>NM_005157</Genbank_ACCN>
    <Protein_ACCN>NP_005148</Protein_ACCN>
    <HGNC_ID>76</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/25</Gene_URL>
    <UCSC_ID>uc004bzw.3</UCSC_ID>
    <EMBL_ID>ENSG00000097007</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P31947</Uniprot_ID>
      <Gene_Name>SFN</Gene_Name>
      <EBI_ID>EBI-476295</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-476295</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8IZP0</Uniprot_ID>
      <Gene_Name>ABI1</Gene_Name>
      <EBI_ID>EBI-375446</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-375446</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P16333</Uniprot_ID>
      <Gene_Name>NCK1</Gene_Name>
      <EBI_ID>EBI-389883</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-389883</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13671</Uniprot_ID>
      <Gene_Name>RIN1</Gene_Name>
      <EBI_ID>EBI-366017</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-366017</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O43900</Uniprot_ID>
      <Gene_Name>PRICKLE3</Gene_Name>
      <EBI_ID>EBI-1751761</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-1751761</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q07890</Uniprot_ID>
      <Gene_Name>SOS2</Gene_Name>
      <EBI_ID>EBI-298181</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-298181</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14315</Uniprot_ID>
      <Gene_Name>FLNC</Gene_Name>
      <EBI_ID>EBI-489954</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-489954</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92918</Uniprot_ID>
      <Gene_Name>MAP4K1</Gene_Name>
      <EBI_ID>EBI-881</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-881</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P63104</Uniprot_ID>
      <Gene_Name>YWHAZ</Gene_Name>
      <EBI_ID>EBI-347088</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-347088</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9BX66</Uniprot_ID>
      <Gene_Name>SORBS1</Gene_Name>
      <EBI_ID>EBI-433642</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-433642</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q86UR5</Uniprot_ID>
      <Gene_Name>RIMS1</Gene_Name>
      <EBI_ID>EBI-1043236</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-1043236</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O75751</Uniprot_ID>
      <Gene_Name>SLC22A3</Gene_Name>
      <EBI_ID>EBI-1752674</EBI_ID>
      <PPI_EBI_URL>EBI-375543,EBI-1752674</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Leukemia, Acute Lymphoblastic 3</Disease_Name>
      <Disease_Detail>Acute Lymphoblastic Leukemia</Disease_Detail>
      <Disease_DB>LKM060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leukemia_acute_lymphoblastic_3?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Myeloid Leukemia</Disease_Name>
      <Disease_Detail>Chronic Myeloid Leukemia</Disease_Detail>
      <Disease_DB>CHR065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_myeloid_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Biphenotypic Leukemia</Disease_Name>
      <Disease_Detail>Acute Biphenotypic Leukemia</Disease_Detail>
      <Disease_DB>ACT095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_biphenotypic_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Lymphoblastic Leukemia</Disease_Name>
      <Disease_Detail>Acute Lymphoblastic Leukemia</Disease_Detail>
      <Disease_DB>ACT101</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_lymphoblastic_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Philadelphia-Negative Chronic Myeloid Leukemia</Disease_Name>
      <Disease_Detail>Philadelphia-Negative Chronic Myeloid Leukemia</Disease_Detail>
      <Disease_DB>PHL007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/philadelphia_negative_chronic_myeloid_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphoblastic Leukemia</Disease_Name>
      <Disease_Detail>Lymphoblastic Leukemia</Disease_Detail>
      <Disease_DB>LYM026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphoblastic_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastrointestinal Stromal Tumor</Disease_Name>
      <Disease_Detail>Gastrointestinal Stromal Tumor</Disease_Detail>
      <Disease_DB>GST019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastrointestinal_stromal_tumor?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Precursor T-Cell Acute Lymphoblastic Leukemia</Disease_Name>
      <Disease_Detail>Precursor T-Cell Acute Lymphoblastic Leukemia</Disease_Detail>
      <Disease_DB>PRC049</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/precursor_t_cell_acute_lymphoblastic_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myeloid Leukemia</Disease_Name>
      <Disease_Detail>Myeloid Leukemia</Disease_Detail>
      <Disease_DB>MYL006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myeloid_leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leukemia</Disease_Name>
      <Disease_Detail>Leukemia</Disease_Detail>
      <Disease_DB>LKM002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leukemia?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bone Marrow Cancer</Disease_Name>
      <Disease_Detail>Bone Marrow Cancer</Disease_Detail>
      <Disease_DB>BNM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bone_marrow_cancer?search=ABL1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leukemia, Philadelphia Chromosome-Positive, Resistant to Imatinib</Disease_Name>
      <Disease_Detail>Leukemia</Disease_Detail>
      <Disease_DB>LKM019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leukemia_philadelphia_chromosome_positive_resistant_to_imatinib?search=ABL1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Human Abl kinase domain in complex with imatinib (STI571, Glivec)</PDB_Title>
      <PDB_ID>2HYY</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HYY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL- 3-(4-PYRIDIN-3-YL-PYRIMIDIN-2
-YLAMINO)-PHENYL]- BENZAMIDE</Ligand_Name>
      <PubMed_Title>Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.</PubMed_Title>
      <Author>Cowan-Jacob, S.W., et.al</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006 Dec 13.</Journal>
      <PubMed_ID>17164530</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain</PDB_Title>
      <PDB_ID>2G2I</PDB_ID>
      <Resolution>3.12</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2G2I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-DIPHOSPHATE</Ligand_Name>
      <PubMed_Title>A Src-like inactive conformation in the abl tyrosine kinase domain.</PubMed_Title>
      <Author>Levinson, N.M., et.al</Author>
      <Journal>PLoS Biol. 2006 May;4(5):e144. Epub 2006 May 2.</Journal>
      <PubMed_ID>16640460</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhibitor</PDB_Title>
      <PDB_ID>2HIW</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HIW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>7-AMINO-1-METHYL-3-(2-METHYL-5-{[3-(TRIFLUOROMETHYL)BENZOYL]AMINO}PHENYL)- 2-OXO
-2,3-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN- 1-IUM</Ligand_Name>
      <PubMed_Title>A general strategy for creating &quot;inactive-conformation&quot; abl inhibitors.</PubMed_Title>
      <Author>Okram, B., et.al</Author>
      <Journal>Chem Biol. 2006 Jul;13(7):779-86.</Journal>
      <PubMed_ID>16873026</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114Q mutant of ABL-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions</PDB_Title>
      <PDB_ID>3EG1</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EG1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>SULFATE ION</Ligand_Name>
      <PubMed_Title>Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.</PubMed_Title>
      <Author>Palencia, A.,  et.al</Author>
      <Journal>J Biol Chem. 2010 Jan 22;285(4):2823-33. Epub 2009 Nov 10.</Journal>
      <PubMed_ID>19906645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114Q mutant of ABL-SH3 domain</PDB_Title>
      <PDB_ID>3EG3</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EG3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GLYCEROL</Ligand_Name>
      <PubMed_Title>Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.</PubMed_Title>
      <Author>Palencia, A.,  et.al</Author>
      <Journal>J Biol Chem. 2010 Jan 22;285(4):2823-33. Epub 2009 Nov 10.</Journal>
      <PubMed_ID>19906645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE SOLUTION NMR STRUCTURE OF ABL SH3 AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1AWO</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1AWO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.</PubMed_Title>
      <Author>Gosser, Y.Q. et.al</Author>
      <Journal>Structure. 1995 Oct 15;3(10):1075-86.</Journal>
      <PubMed_ID>8590002</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain</PDB_Title>
      <PDB_ID>2G2F</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2G2F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>THIOPHOSPHORIC ACID O-((ADENOSYL-PHOSPHO)PHOSPHO)- S-ACETAMIDYL-DIESTER $ PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>A Src-like inactive conformation in the abl tyrosine kinase domain.</PubMed_Title>
      <Author>Levinson, N.M., et.al</Author>
      <Journal>PLoS Biol. 2006 May;4(5):e144. Epub 2006 May 2.</Journal>
      <PubMed_ID>16640460</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Abl kinase domain in complex with NVP-AEG082</PDB_Title>
      <PDB_ID>2HZ4</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HZ4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2,3,4-TETRAHYDROGEN-STAUROSPORINE</Ligand_Name>
      <PubMed_Title>Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.</PubMed_Title>
      <Author>Cowan-Jacob, S.W., et.al</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006 Dec 13.</Journal>
      <PubMed_ID>17164530</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114T mutant of ABL-SH3 domain</PDB_Title>
      <PDB_ID>3EG0</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EG0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GLYCEROL</Ligand_Name>
      <PubMed_Title>Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.</PubMed_Title>
      <Author>Palencia, A.,  et.al</Author>
      <Journal>J Biol Chem. 2010 Jan 22;285(4):2823-33. Epub 2009 Nov 10.</Journal>
      <PubMed_ID>19906645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain</PDB_Title>
      <PDB_ID>2G1T</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2G1T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>THIOPHOSPHORIC ACID O-((ADENOSYL-PHOSPHO)PHOSPHO)- S-ACETAMIDYL-DIESTER $ MAGNESIUM ION</Ligand_Name>
      <PubMed_Title>A Src-like inactive conformation in the abl tyrosine kinase domain.</PubMed_Title>
      <Author>Levinson, N.M., et.al</Author>
      <Journal>PLoS Biol. 2006 May;4(5):e144. Epub 2006 May 2.</Journal>
      <PubMed_ID>16640460</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMPLICATIONS FOR SH3-LIGAND INTERACTIONS</PDB_Title>
      <PDB_ID>1BBZ</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1BBZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>SULFATE ION</Ligand_Name>
      <PubMed_Title>Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.</PubMed_Title>
      <Author>Pisabarro, M.T.,et.al</Author>
      <Journal>J Mol Biol. 1998 Aug 21;281(3):513-21.</Journal>
      <PubMed_ID>9698566</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Tyrosine-protein kinase ABL1</PDB_Title>
      <PDB_ID>1ABL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <Has_Ligand>No</Has_Ligand>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the c-Abl kinase domain in complex with INNO-406</PDB_Title>
      <PDB_ID>2E2B</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2E2B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[3-(4,5'-BIPYRIMIDIN-2-YLAMINO)-4-METHYLPHENYL]- 4-{[(3S)-3-
(DIMETHYLAMINO)PYRROLIDIN-1-YL]METHYL}- 3-(TRIFLUOROMETHYL)BENZAMIDE</Ligand_Name>
      <PubMed_Title>Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.</PubMed_Title>
      <Author>Horio, T., et.al</Author>
      <Journal>Bioorg Med Chem Lett. 2007 May 15;17(10):2712-7. Epub 2007 Mar 3.</Journal>
      <PubMed_ID>17376680</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL</PDB_Title>
      <PDB_ID>1AB2</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1AB2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Three-dimensional solution structure of the src homology 2 domain of c-abl.</PubMed_Title>
      <Author>Overduin, M.,et.al</Author>
      <Journal>Cell. 1992 Aug 21;70(4):697-704.</Journal>
      <PubMed_ID>1505033</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain</PDB_Title>
      <PDB_ID>2G2H</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2G2H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}- 8-METHYLPYRIDO[2,3
-D]PYRIMIDIN-7(8H)-ONE</Ligand_Name>
      <PubMed_Title>A Src-like inactive conformation in the abl tyrosine kinase domain.</PubMed_Title>
      <Author>Levinson, N.M., et.al</Author>
      <Journal>PLoS Biol. 2006 May;4(5):e144. Epub 2006 May 2.</Journal>
      <PubMed_ID>16640460</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the F-actin binding domain of Bcr-Abl/c-Abl</PDB_Title>
      <PDB_ID>1ZZP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1ZZP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.</PubMed_Title>
      <Author>Hantschel, O., et.al</Author>
      <Journal>Mol Cell. 2005 Aug 19;19(4):461-73.</Journal>
      <PubMed_ID>16109371</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Abl kinase domain in complex with NVP-AEG082</PDB_Title>
      <PDB_ID>2HZ0</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HZ0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}- N-[4-PROPYL-3-
(TRIFLUOROMETHYL)PHENYL]BENZAMIDE</Ligand_Name>
      <PubMed_Title>Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.</PubMed_Title>
      <Author>Cowan-Jacob, S.W., et.al</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006 Dec 13.</Journal>
      <PubMed_ID>17164530</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectroscopy</PDB_Title>
      <PDB_ID>1JU5</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1JU5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.</PubMed_Title>
      <Author>Donaldson, L.W.,et.al</Author>
      <Journal>Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14053-8. Epub 2002 Oct 16.</Journal>
      <PubMed_ID>12384576</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114Q mutant of ABL-SH3 domain</PDB_Title>
      <PDB_ID>3EG2</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EG2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GLYCEROL</Ligand_Name>
      <PubMed_Title>Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.</PubMed_Title>
      <Author>Palencia, A.,  et.al</Author>
      <Journal>J Biol Chem. 2010 Jan 22;285(4):2823-33. Epub 2009 Nov 10.</Journal>
      <PubMed_ID>19906645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Abl kinase domain in complex with NVP-AEG082</PDB_Title>
      <PDB_ID>2HZI</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HZI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,6-DICHLOROPHENYL)-2-[(4-FLUORO-3-METHYLPHENYL)AMINO]- 8-METHYLPYRIDO[2,3
-D]PYRIMIDIN-7(8H)-ONE</Ligand_Name>
      <PubMed_Title>Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.</PubMed_Title>
      <Author>Cowan-Jacob, S.W., et.al</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006 Dec 13.</Journal>
      <PubMed_ID>17164530</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain</PDB_Title>
      <PDB_ID>2GQG</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2GQG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN- 1-YL]-2
-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE- 5-CARBOXAMIDE $ GLYCEROL</Ligand_Name>
      <PubMed_Title>The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.</PubMed_Title>
      <Author>Tokarski, J.S.,et.al</Author>
      <Journal>Cancer Res. 2006 Jun 1;66(11):5790-7.</Journal>
      <PubMed_ID>16740718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114A mutant of ABL-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions</PDB_Title>
      <PDB_ID>2O88</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2O88</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>SULFATE ION</Ligand_Name>
      <PubMed_Title>Crystallization by capillary counter-diffusion and structure determination of the N114A mutant of the SH3 domain of Abl tyrosine kinase complexed with a high-affinity peptide ligand.</PubMed_Title>
      <Author>Camara-Artigas, A., et.al</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2007 May;63(Pt 5):646-52. Epub 2007 Apr 21.</Journal>
      <PubMed_ID>17452790</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358</PDB_Title>
      <PDB_ID>2V7A</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2V7A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[(3E)-5-[(2R)-2-METHOXY-2-PHENYLACETYL]PYRROLO[3,4- C]PYRAZOL-3(5H)-YLIDENE]-4
-(4-METHYLPIPERAZIN- 1-YL)BENZAMIDE $ MAGNESIUM ION</Ligand_Name>
      <PubMed_Title>Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.</PubMed_Title>
      <Author>Modugno, M.,et.al</Author>
      <Journal>Cancer Res. 2007 Sep 1;67(17):7987-90.</Journal>
      <PubMed_ID>17804707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N114Q mutant of ABL-SH3 domain</PDB_Title>
      <PDB_ID>3EGU</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EGU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GLYCEROL $ SULFATE ION</Ligand_Name>
      <PubMed_Title>Role of interfacial water molecules in proline-rich ligand recognition by the Src homology 3 domain of Abl.</PubMed_Title>
      <Author>Palencia, A.,  et.al</Author>
      <Journal>J Biol Chem. 2010 Jan 22;285(4):2823-33. Epub 2009 Nov 10.</Journal>
      <PubMed_ID>19906645</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680</PDB_Title>
      <PDB_ID>2F4J</PDB_ID>
      <Resolution>1.91</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2F4J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CYCLOPROPANECARBOXYLIC ACID {4-[4-(4-METHYL- PIPERAZIN-1-YL)-6-(5-METHYL-2H
-PYRAZOL-3- YLAMINO)-PYRIMIDIN-2-YLSULFANYL]-PHENYL}- AMIDE</Ligand_Name>
      <PubMed_Title>Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.</PubMed_Title>
      <Author>Young, M.A., et.al</Author>
      <Journal>Cancer Res. 2006 Jan 15;66(2):1007-14.</Journal>
      <PubMed_ID>16424036</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the auto-inhibition of c-Abl tyrosine kinase</PDB_Title>
      <PDB_ID>1OPL</PDB_ID>
      <Resolution>3.42</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1OPL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02400001</ASD_Ligand>
      <Ligand_Name>MYRISTIC ACID $ 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}- 8-METHYLPYRIDO[2,3
-D]PYRIMIDIN-7(8H)-ONE</Ligand_Name>
      <PubMed_Title>Structural basis for the autoinhibition of c-Abl tyrosine kinase.</PubMed_Title>
      <Author>Nagar, B., et.al</Author>
      <Journal>Cell. 2003 Mar 21;112(6):859-71.</Journal>
      <PubMed_ID>12654251</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery and Characterization of a Cell-Permeable, Small-molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site</PDB_Title>
      <PDB_ID>3PYY</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PYY</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03320008</ASD_Ligand>
      <PubMed_Title>Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site.</PubMed_Title>
      <Author>Yang, J., et al.</Author>
      <Journal>Chem.Biol.(2011)18:177-186</Journal>
      <PubMed_ID>21338916</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SH3-SH2 DOMAIN FRAGMENT OF HUMAN BCR-ABL TYROSINE KINASE</PDB_Title>
      <PDB_ID>2ABL</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2ABL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.</PubMed_Title>
      <Author>Nam, H.J., et.al</Author>
      <Journal>Structure. 1996 Sep 15;4(9):1105-14.</Journal>
      <PubMed_ID>8805596</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase</PDB_Title>
      <PDB_ID>2FO0</PDB_ID>
      <Resolution>2.27</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2FO0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>GLYCEROL $ MYRISTIC ACID $ 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}- 8-METHYLPYRIDO[2,3
-D]PYRIMIDIN-7(8H)-ONE</Ligand_Name>
      <PubMed_Title>Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.</PubMed_Title>
      <Author>Nagar, B., et.al</Author>
      <Journal>Mol Cell. 2006 Mar 17;21(6):787-98.</Journal>
      <PubMed_ID>16543148</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human ABL kinase in complex with nilotinib</PDB_Title>
      <PDB_ID>3CS9</PDB_ID>
      <Resolution>2.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3CS9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>Nilotinib</Ligand_Name>
      <PubMed_Title>Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.</PubMed_Title>
      <Author>Weisberg, E., et.al</Author>
      <Journal>Cancer Cell. 2005 Feb;7(2):129-41.</Journal>
      <PubMed_ID>15710326</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05130</Pathway_ID>
      <Pathway_Title>Pathogenic Escherichia coli infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04014</Pathway_ID>
      <Pathway_Title>Ras signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05416</Pathway_ID>
      <Pathway_Title>Viral myocarditis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cardiovascular diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05220</Pathway_ID>
      <Pathway_Title>Chronic myeloid leukemia</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04722</Pathway_ID>
      <Pathway_Title>Neurotrophin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04360</Pathway_ID>
      <Pathway_Title>Axon guidance</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04110</Pathway_ID>
      <Pathway_Title>Cell cycle</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05131</Pathway_ID>
      <Pathway_Title>Shigellosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://www.cathdb.info/pdb/1ab2</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1ab2</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>range,381,383,DFGmotif;site,344,Ala;site,337,Ala</Site_Detail>
      <Site_Reference>Liu Y, et al. Nat Chem Biol. 2006,2(7):358-364.;Xiong X, et al. Biochim.Biophys.Acta. 2008,1783(5):737-747.;Adrian FJ, et al. Nat Chem Biol. 2006,2(2):95-102.</Site_Reference>
      <Site_Type>Peptides-induced</Site_Type>
      <PubMed_ID>16783341;18328268;16415863</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.2</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/2.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00740007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02400001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320026</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320048</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320052</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320059</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320060</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320061</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320065</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320066</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320067</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320068</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320069</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320070</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320071</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320072</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320074</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320075</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320076</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320077</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320078</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320079</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320080</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320081</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320082</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320083</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320084</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320085</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320086</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320087</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320089</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320091</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320093</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320094</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320095</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320096</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320097</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320098</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320100</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320102</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320103</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320104</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320105</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320107</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320108</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320109</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320110</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320111</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320112</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320113</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320114</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320115</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320116</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320117</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320118</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320119</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320120</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320121</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320122</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320123</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320124</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320125</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320126</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320127</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320128</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320129</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320130</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320131</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320132</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320133</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320134</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320135</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320137</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320138</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320139</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320140</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320142</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320143</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320144</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320145</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320146</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320147</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320148</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320149</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320151</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320152</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320153</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320154</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320155</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320157</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320158</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320159</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03320160</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>